Literature DB >> 10660500

Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998.

G S Babini1, D M Livermore.   

Abstract

A 1994 survey of 35 intensive care units (ICUs) in Western and Southern Europe found extended-spectrum beta-lactamases (ESBLs) in 220/966 (23%) klebsiellae. A follow-up survey from May 1997 to October 1998 collected klebsiellae from 24 ICUs, including 23 that participated in 1994. Twenty-one ICUs sent 433 eligible isolates, of which 110 (25%) had ESBLs. The prevalence of ESBLs had not changed significantly from 1994 but the proportion of ESBL-producers resistant to piperacillin/tazobactam had risen from 31% to 63% (P < 0.001), and most of this resistance was high level (MICs >/= 128 + 4 mg/L). The proportion of Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase rose from 8% in 1994 to 21% in 1997-1998 (P < 0. 001). Most klebsiellae (99%) were very susceptible to meropenem (mode MIC 0.03 mg/L) but three had decreased susceptibility (MICs 2-4 mg/L). These could not hydrolyse carbapenems. Aminoglycoside resistance was not significantly changed in prevalence from 1994; ciprofloxacin resistance occurred in 31% of ESBL-producers in both years, but had increased among non-producers (2% in 1994 versus 7% in 1997-1998, P < 0.001).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660500     DOI: 10.1093/jac/45.2.183

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  33 in total

1.  A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group.

Authors:  C De Champs; D Sirot; C Chanal; R Bonnet; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Are SHV beta-lactamases universal in Klebsiella pneumoniae?

Authors:  G S Babini; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium.

Authors:  Armine M Sefton
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates.

Authors:  Teresa Spanu; Maurizio Sanguinetti; Mario Tumbarello; Tiziana D'Inzeo; Barbara Fiori; Brunella Posteraro; Rosaria Santangelo; Roberto Cauda; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

6.  Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.

Authors:  Emma Padilla; Diana Alonso; Antonio Doménech-Sánchez; Cristina Gomez; José Luis Pérez; Sebastián Albertí; Nuria Borrell
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

8.  Evaluation of screening methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

Authors:  Thean Yen Tan; Lily Siew Yong Ng; Jie He; Tse Hsien Koh; Li Yang Hsu
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.

Authors:  Jeroen P Jansen; Ritesh Kumar; Yehuda Carmeli
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Extended Spectrum Beta-lactamase Detection in Gram-negative Bacilli of Nosocomial Origin.

Authors:  Dechen C Tsering; Shyamasree Das; Luna Adhiakari; Ranabir Pal; Takhellambam Sk Singh
Journal:  J Glob Infect Dis       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.